Related Experiment Video
Updated: Jul 6, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice
Published on: October 3, 2011
Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects
Joseph Wong1, Andrew Brugger, Atul Khare
1Baxter Pharmaceuticals and Technologies, Global Research and Development, Baxter Healthcare Corporation, 25212 West Illinois Route 120, Round Lake, IL 60073-0490, USA. joe_wong@baxter.com
Abstract:
There has been growing interest in nanoparticles as an approach to formulate poorly soluble drugs. Besides enhanced dissolution rates, and thereby, improved bioavailability, nanoparticles can also provide targeting capabilities when injected intravenously. The latter property has led to increased research and development activities for intravenous suspensions. The first intravenously administered nanoparticulate product, Abraxane (a reformulation of paclitaxel), was approved by the FDA in 2006. Additional clinical trials have been conducted or are ongoing for multiple other indications such as oncology, infective diseases, and restenosis. This article reviews various challenges associated with developing intravenous nanosuspension dosage forms. In addition, various formulation considerations specific to intravenous nanosuspensions as well as reported findings from various clinical studies have been discussed.
Related Concept Videos
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
IV Infusion to Oral Dosing: Conversion Methods
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
